alexa 2-3 Months Safety And Efficacy In AMD Patients Treated With Ziv-Aflibercept | 61209
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

10th International Conference on Clinical & Experimental Ophthalmology
November 21-23, 2016 Dubai, UAE

Muhammad H Younis
University Medical Center-Rizk Hospital, Lebanon
Posters & Accepted Abstracts: J Clin Exp Ophthalmol
DOI: 10.4172/2155-9570.C1.049
Abstract
Background & Aim: Aflibercept is an approved therapy for neovascular macular degeneration (AMD) while ziv-aflibercept is approved for oncology and is cost-effective relative to the expensive same molecule aflibercept. In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using ziv-aflibercept. Our purpose is to ascertain the 3-month safety and efficacy in AMD treated with intra-vitreal ziv-aflibercept. Methods: Prospectively, consecutive patients with wet age related macular degeneration that required aflibercept underwent zivaflibercept intra-vitreal injection of 0.05 ml of compounded ziv-aflibercept (1.25 mg) from March 2015 to November 2015 in the Lebanese series and scattered select cases in the Indian cases. Monitoring of best-corrected visual acuity, intraocular inflammation, cataract progression and retinal structure by spectral domain OCT were carried initially, one week, one month, two months and three months after injections. The study received Institutional Review Board approval and received the registration NCT02486484. Results: 30 eyes were treated (22 Caucasians, 8 Indians; 16 men, 14 women; 14 right eye and 16 right eye) with mean age of 74.3 years with 11 naïve cases and 19 having had prior injections 4 months prior to our treatment. Best-corrected visual acuity improved from baseline logMar 1.08 to 0.74 at 1 week, 0.72 at 1 month, 0.67 at 2 month and 0.71 at 3 month (p<0.001 for all time periods). CMT in microns decreased from 332.8 to 302.0 at 1 week, 244.8 at 1 month, 225.9 at 2 months and 208.2 at 3 month (p<0.001 for all time periods). There were no signs of intraocular inflammation, or change in lens status throughout the study. Intraocular pressure was unchanged initial and at 3 month in 10 eyes (12.8±2.3 mmHg vs. 12.8±2.2 mmHg). Significance was also present for the Lebanese series alone and for virgin cases in the Lebanese series. Conclusions: Off label use of ziv-aflibercept improves visual acuity, without ocular toxicity and offers a cheaper alternative to the same molecule aflibercept, especially in the third world.
Biography

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immun[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version